Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) Revenue (2016 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed Revenue for 12 consecutive years, with $40637.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Revenue changed N/A year-over-year to $40637.0, compared with a TTM value of $40637.0 through Nov 2024, down 91.87%, and an annual FY2024 reading of $130074.0, down 68.29% over the prior year.
  • Revenue was $40637.0 for Q1 2024 at CNBX Pharmaceuticals, down from $89437.0 in the prior quarter.
  • Across five years, Revenue topped out at $310165.0 in Q2 2023 and bottomed at -$46646.0 in Q2 2022.
  • Average Revenue over 4 years is $58772.7, with a median of $29958.0 recorded in 2022.
  • The sharpest move saw Revenue tumbled 43.53% in 2020, then surged 764.93% in 2023.
  • Year by year, Revenue stood at $2207.0 in 2020, then surged by 1257.41% to $29958.0 in 2022, then surged by 198.54% to $89437.0 in 2023, then crashed by 54.56% to $40637.0 in 2024.
  • Business Quant data shows Revenue for CNBX at $40637.0 in Q1 2024, $89437.0 in Q4 2023, and $100000.0 in Q3 2023.